Navigation Links
Fovea Pharmaceuticals to be Acquired by sanofi-aventis
Date:10/1/2009

PARIS, Oct. 1 /PRNewswire/ -- Fovea Pharmaceuticals announced today that it has entered into a binding agreement with sanofi-aventis to sell 100% of its share to sanofi-aventis. Fovea has a portfolio of three clinical compounds, a unique technology platform and several discovery programs dedicated to back of the eye diseases. The deal is valued to a total of euro 370M, including an immediate upfront payment and subsequent milestone payments related to the progress of the clinical compounds. The closing of the transaction is expected to occur in the 4th quarter of 2009.

Fovea was created in 2005 by Professeur Jose A. Sahel, Bernard Gilly and Pierre Belichard, with the initial seeding of Sofinnova Partners in Paris. It successfully raised two rounds of funding in November 2005 and February 2008, from a syndicate of pan-european investors including Sofinnova Partners, Abingworth Management, Forbion Capital Partners, The Wellcome Trust, GIMV, Credit Agricole Private Equity and Vesalius BioCapital.

Fovea has rapidly built a pipeline of products: FOV 1101, an eye drop, fixed dose combination of prednisolone and cyclosporine, currently in phase II for the treatment of persistent allergic conjunctivitis, FOV 2302, an intravitreal formulation of a plasma kallikrein inhibitor, in phase I for the treatment of Retinal Vein Occlusion induced macular edema and FOV 2304, a potent antagonist of bradykinin B1 receptor, active by eye drop, scheduled to enter in phase I by November 2009 for the treatment of diabetic macular oedema.

"Our team is proud and extremely pleased to join sanofi-aventis, as it will provide the necessary resources and expertise needed to continue to aggressively build the ophthalmology franchise and demonstrate the efficacy of our products through regulatory clinical development," commented Bernard Gilly, President and Chief Executive Officer of Fovea Pharmaceuticals. "It also demonstrates that strong science combined with high level expertise in pharmaceutical development and management is what the industry leaders are looking for."

Fovea was built upon close relationship with the Vision Institute, created and chaired by Professeur Jose A. Sahel, at the National Eye Hospital in Paris. The Vision Institute mixes on the same campus research teams from UPMC, INSERM, CNRS, a clinical investigation centre dedicated to retinal diseases, high level clinicians and start-up companies like Fovea, putting the patients at the centre of the development of new therapeutic approaches.

About Fovea Pharmaceuticals

Fovea Pharmaceuticals SA (Fovea) is a privately-held biopharmaceutical company specialized in development and commercialization of drugs for the treatment of ocular diseases, with a special focus on retinal pathologies. It has raised two rounds of financing. For more information, please visit www.fovea-pharma.com .

    Fovea Pharmaceuticals SA:
    Bernard Davitian
    Chief Financial Officer
    +33 1 44 16 42 61
    info@fovea-pharma.com

    Fovea Press Contact U.S.:
    Martina Schwarzkopf, Ph.D.
    Russo Partners, LLC
    +1 212-845-4292
    martina.schwarzkopf@russopartnersllc.com

SOURCE Fovea Pharmaceuticals SA


'/>"/>
SOURCE Fovea Pharmaceuticals SA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
2. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
3. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
4. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
5. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
6. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
7. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
8. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
9. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
10. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
11. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/22/2017)... ROCKVILLE, Md. , Sept. 22, 2017  As ... by Republican Senators Bill Cassidy (R-LA) and ... Kalorama Information notes that the medical device industry is ... the medical device tax, the 2.3% excise tax on ... Act.  But they also want covered patients, increased visits ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Mohebi Hair Restoration, has recently contributed a medical article to the newly revamped ... cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward ... Berkeley, and other leading institutions in announcing the launch of the Leadership ... the way animals are raised for food. , Founding members of the Leadership ...
Breaking Medicine News(10 mins):